It was during a dream solo three-month trip to the Bahamas in July 2022 that Louisa Lloyd realised something was seriously ...

My heart aches for the woman who has endured such profound and relentless hardship. From a life-threatening autoimmune disorder to the devastating diagnosis of ...

Therefore, this is a matter that is important to discuss in detail, especially as the lingering effects of period poverty ...

The pre-analytical workflow is one of the primary considerations in the successful use of liquid biopsies for cancer ...

A CANCER survivor is looking to prove that the disease doesn’t have one look – instead getting ready to show her gothic style and tattoos on ...

An NHS GP has highlighted the early signs of a killer disease - which has risen by a shocking amount in recent years. Dr Mark ...

INX-315, a CDK2 inhibitor, gained FDA fast track status in CCNE1-positive platinum-resistant/refractory ovarian cancer.

Researchers at Karolinska Institutet have uncovered a unique ability of a special subtype of natural killer cells in the ...

The selective CDK2 inhibitor INX-315 has been given FDA fast track designation for use in CCNE1-amplified, platinum-resistant ...

DB-1305/BNT325 was generally well tolerated and exhibited “very encouraging and durable antitumor activity in ovarian cancer patients,” said Maria Rubinstein, MD.

INX-315, a CDK2 inhibitor, received FDA fast track designation for patients with CCNE1-amplified platinum-resistant ovarian ...